Gelonghui June 14th 丨Xinrui Pharmaceutical (06108.HK) announced that on June 14, 2022, the company has granted share purchase rights to a number of eligible persons in accordance with the share option plan to subscribe for a total of 143.2 million common shares with a face value of HK$0.05 per share of the company's share capital.
新锐医药(06108.HK)授出合共1.432亿份购股权
Emerging Pharmaceuticals (06108.HK) granted a total of 143.2 million share options
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.